Background Schizophrenia is a common, severe, and usually chronic disorder. Maintenance
treatment with antipsychotic drugs can prevent relapse but also causes side-effects. We …

Schizophrenia is associated with substantial unmet needs, highlighting the necessity for
new treatments. This narrative review compares the pharmacology, clinical trial data and …

Background The symptoms and signs of schizophrenia have been linked to high levels of
dopamine in specific areas of the brain (limbic system). Antipsychotic drugs block the …

Second generation antipsychotics (SGAs) are effective options in the treatment of
schizophrenia and mood disorders, each with characteristic efficacy and safety features. In …

Abstract Purpose of Review Over the last ten years, the treatment of psychosis has seen a
near explosion of creative development in both novel agents and new delivery modalities …

Dopamine receptor partial agonists (DRPAs; aripiprazole, brexpiprazole, and cariprazine)
constitute a novel class of antipsychotics. Although they share a similar mechanism of …

Aripiprazole, brexpiprazole and cariprazine differ from all other second-generation
antipsychotics due to partial agonism at the dopamine D2 and D3 receptors. In contrast to …

In 2002, the first III generation antipsychotic drug was registered—aripiprazole. Its partial
dopaminergic agonism underlies its unique mechanism of action and the potentially …

Introduction Avoidance of relapse is the main aim of long-term antipsychotic treatment in
schizophrenia, yet how 'relapse'is defined in trials is not well-known. Methods We conducted …

Abstract Brexpiprazole (Rxulti®, Rexulti®) is an oral atypical antipsychotic agent approved
for the treatment of schizophrenia in the EU (in adult patients) and the USA, as well as in …